

Abstract

5 The present invention can be used in pharmacology
specifically in the preparation of interferon-containing
compositions, which are capable of conserving their
biological activity and can be administrated intranasally,
e.g. in the preparation of nasal drops. This invention
essentially refers to an antiviral agent in the form of
10 nasal drops that contains a genetically engineered alpha,
beta or gamma interferon with a viscosity of $(1.1 - 30.0) \text{ Pa}\cdot\text{s}$, a biocompatible polymer and a buffer mixture. The
agent may further include an antioxidant, and the
ingredients are contained in the following amounts per ml
15 buffer mixture: 1,000 to 5,000 IU of genetically engineered
interferon; 0.005 to 0.714 g of biocompatible polymer; and
0.0001 to 0.0008 g of an antioxidant. Trilon B is used as
the antioxidant, whereas polyvinylpyrrolidone and/or
polyethylene oxide is (are) used as the biocompatible
20 polymer(s) at polyvinylpyrrolidone/polyethylene oxide ratio
is 1:1 - 50.